Key result
Non-viral delivery methods offer diverse strategies to efficiently deliver CRISPR-Cas ribonucleoprotein to hematopoietic stem cells.
Why the study?
Effective delivery of CRISPR/Cas ribonucleoprotein complexes to hematopoietic stem cells remains a critical hurdle for advancing gene editing therapies for hematologic disorders.
This review highlights emerging non-viral delivery methods for CRISPR-Cas RNP complexes to hematopoietic stem cells, offering potential for safer and more efficient gene editing.
Answers are grounded in this paper and cite their sources.
RNP delivery may advance HSC gene editing for hematologic disorders; leaves open prospective clinical validation.
Gene manipulation of hematopoietic stem cells (HSCs) using the CRISPR/Cas system as a potent genome editing tool holds immense promise for addressing hematologic disorders. An essential hurdle in advancing this treatment lies in effectively delivering CRISPR/Cas to HSCs. While various delivery formats exist, Ribonucleoprotein complex (RNP) emerges as a particularly efficient option. RNP complexes offer enhanced gene editing capabilities, devoid of viral vectors, with rapid activity and minimized off-target effects. Nevertheless, novel delivery methods such as microfluidic-based techniques, filtroporation, nanoparticles, and cell-penetrating peptides are continually evolving. This study aims to provide a comprehensive review of these methods and the recent research on delivery approaches of RNP complexes to HSCs.
No takes yet. Share an insight, caveat, or question.
Molaei et al. (2024) conducted a review in Hematologic disorders. Non-viral delivery methods for CRISPR-Cas ribonucleoprotein was evaluated. Non-viral delivery methods, including electroporation, microfluidics, filtroporation, and nanoparticles, offer diverse strategies for efficiently delivering CRISPR-Cas ribonucleoprotein to hematopoietic stem cells.
Synapse has enriched 10 related papers. Consider them for comparative context: